ArticleCost effectiveness and resource allocation : C/E2025
A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran.
Mojtaba Jafari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.